For individuals living with Parkinson’s disease and the families who support them, advancements in treatment offer new possibilities for managing symptoms and maintaining independence.
In September 2026, the U.S. Food and Drug Administration (FDA) approved tavapadon, a new once-daily medication designed to treat the movement-related symptoms of Parkinson’s disease. Marketed under the brand name Juvmo, the medication represents another option for individuals seeking relief from tremors, stiffness, and slowed movement.
While tavapadon is not a cure for Parkinson’s disease, its approval marks an important step in expanding the treatments available to patients and their healthcare providers.
Understanding How Tavapadon Works
Parkinson’s disease is a progressive neurological condition that affects movement, balance, coordination, and other essential functions. The disease is associated with a reduction in dopamine, a chemical messenger in the brain that helps regulate movement.
Many existing Parkinson’s medications work by replacing or mimicking dopamine to improve movement-related symptoms.
Tavapadon belongs to a class of medications called dopamine agonists, which activate dopamine receptors in the brain. However, unlike some earlier medications in this category, tavapadon selectively targets receptors associated with movement.
Researchers believe this more targeted approach could help manage Parkinson’s symptoms while potentially reducing certain side effects associated with traditional dopamine agonists.
The medication is taken orally once a day and may be prescribed independently or alongside other Parkinson’s treatments, depending on an individual’s needs.
What Did Clinical Trials Reveal?
Before receiving FDA approval, tavapadon was evaluated through a series of Phase III clinical trials known as the TEMPO studies.
Researchers studied the medication in individuals recently diagnosed with Parkinson’s disease, as well as those experiencing more advanced symptoms.
The results showed improvements in movement-related symptoms, including tremors, stiffness, and slowed movement. Participants with earlier-stage Parkinson’s also demonstrated improvements in everyday activities such as dressing, eating, and personal care.
For individuals already taking levodopa, another commonly prescribed Parkinson’s medication, adding tavapadon provided an average of approximately one additional hour per day of improved symptom control without troublesome involuntary movements.
This improvement is particularly meaningful because Parkinson’s symptoms often fluctuate throughout the day, making routine activities unpredictable.
Although results have been encouraging, tavapadon can still cause side effects, including nausea, headaches, and dizziness. Other potential concerns include hallucinations, low blood pressure, and involuntary movements. Additional research is underway to better understand its long-term safety and effectiveness.
What Does This Approval Mean for Families?
For families navigating Parkinson’s disease, treatment advancements can provide additional opportunities to maintain quality of life.
Symptoms such as tremors, muscle stiffness, and difficulty walking can gradually make familiar activities more challenging. When these symptoms become less predictable, individuals may need greater assistance with personal care, mobility, and daily routines.
The availability of another medication gives healthcare providers additional flexibility when developing individualized treatment plans.
However, Parkinson’s affects everyone differently. A medication that works well for one individual may not be appropriate for another.
Families should discuss new treatments with their loved one’s neurologist before considering changes to an existing medication routine.
The Importance of Specialized Parkinson’s Care
While medical advancements continue to improve treatment possibilities, individuals living with Parkinson’s may also benefit from specialized daily support.
Parkinson’s care often involves managing movement-related challenges alongside changes in cognition, sleep, mood, and other aspects of health.
Having access to caregivers who understand these challenges can help individuals navigate their daily routines while maintaining as much independence as possible.
At The Kensington White Plains, we recognize that Parkinson’s care requires an individualized approach.
As a Certified Community Partner in Parkinson’s Care through the Parkinson’s Foundation, our community is committed to supporting individuals living with Parkinson’s through care practices that address movement, non-movement, and cognitive symptoms.
Our team works closely with residents and their families to provide personalized assistance, promote engagement, and support changing care needs.
Looking Ahead With Hope and Support
The FDA approval of tavapadon highlights continued progress in Parkinson’s research and treatment.
Although there is currently no cure, advancements in medication, combined with specialized care and a supportive environment, can help individuals and families navigate the challenges of Parkinson’s disease.
At The Kensington White Plains, our promise is to love and care for your family as we do our own. If your loved one is living with Parkinson’s disease and could benefit from additional support, learn more about our specialized Parkinson’s care or schedule a visit to discover how our team can help.